A Randomized Double-Blind Controlled Trial of Bicyclol in Treatment of Chronic Hepatitis B

姚光弼,计焱焱,王勤环,周霞秋,徐道振,陈新月,张清波

DOI: https://doi.org/10.3969/j.issn.1007-7669.2002.08.003

2002-01-01

Abstract:AIM: To evaluate the efficacy and safety of bicyclol for chronic hepatits B(CHB). METHODS: CHB patients were randomly divided into bicyclol group and bifendate group on the ratio of 2∶1. Each group of patients received bicyclol or bifendate 2 mg tid for 24 wk, then stopped treatment and followed up 12 wk. Investigating items included clinical symptoms, liver function tests, serum hepatitis B (HBV) markers and safety profile. Efficacy evaluation was based on Intent To Treat (ITT) principle. RESULTS: Bicyclol or bifendate were given to two hundred and sixty nine and one hundred and thirty eight patients, respectively. The demographic and baseline features were similar in both groups. After bicyclol therapy, both clinical symptoms and serum ALT, AST levels were improved markedly. The normalization rates of ALT and AST were 53.5 % and 48.7 % at wk 24, and kept sustained normal in 40.2 % and 48.7 % at 12 wk after stop of treatment. In bifendate group, the ALT and AST normalization rates were 61.6 % and 44.2 % at wk 24, and 45.7 % and 50.0 % at 12 wk after stop of the treatment, respectively. The improvement of serum ALT and AST showed no statistical difference between two groups ( P 0.05). Regarding the HBV markers, in bicyclol group the negativity of HBeAg, HBeAg/Anti HBe seroconversion and negativity of HBV DNA at wk 24 were 20.8 % 15.6 % and 39.0 %, respectively, and then 29.0 %, 20.8 % and 45.7 % and 12 wk after stop of treatment. Whereas in bifendate group, those parameters were 15.2 %, 9.4 % and 37.7 % at wk 24, and 21.0 %, 14.5 % and 38.4 % at 12 wk after stop of treatment. These results between bicyclol and bifendate groups showed no significant statistical difference. However, in patients whose baseline ALT levels were higher than 5 times of upper limit of normal (200 U·L -1 ), the HBeAg negative rates and seroconversion rates at 12 wk after stop of treatment were significant higher in bicyclol group than those in bifendate group, those were 48 % versus 22 %( P = 0.015) and 38 % versus 12 % ( P =0.01). The adverse reactions of bicyclol group were mild and uncommon, only skin rash and dizzeness were occurred in one patient each; and skin rashes occurred in two and loss of appetite and nausea occurred in one patient who received bifendate. CONCLUSION: Bicyclol is effective for the improvement of the clinical symptoms and serum ALT and AST. Bicyclol is superior to bifendate on the clearance of serum HBeAg and seroconversion. It is well tolerated and safety throughout the course of trial.